| Dordaviprone studied in …STUDIED_INderived29 of 29show fewer |
|---|
| → studied in | NCT05630794Phase 1 · recruiting Testing for Safety and Colorectal Cancer Preventive Effects of ONC201 · 29 trials list this drug (6 active) | — | — | Colorectal Adenomatous Polyp,Multiple Adenomatous Polyps,Colorectal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02392572Phase 1/Phase 2 · terminated ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome · 29 trials list this drug (6 active) | — | — | Acute Lymphoblastic Leukemia,Myelodysplastic Syndrome,Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05476939Phase 3 · recruiting Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0 · 29 trials list this drug (6 active) | — | — | Diffuse Intrinsic Pontine Glioma,Diffuse Midline Glioma,Diffuse Midline Glioma, H3 K27M-Mutant | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05009992Phase 2 · recruiting Combination Therapy for the Treatment of Diffuse Midline Gliomas · 29 trials list this drug (6 active) | — | — | Diffuse Intrinsic Pontine Glioma,WHO Grade 3 Glioma,Diffuse Midline Glioma, H3 K27M-Mutant | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04055649Phase 2 · recruiting ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer · 29 trials list this drug (6 active) | — | — | Malignant Ovarian Epithelial Tumor,Primary Peritoneal Carcinoma,Ovarian Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03932643Phase 1 · completed ONC-201 Maintenance Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome After Stem Cell Transplant · 29 trials list this drug (6 active) | — | — | Myelodysplastic Syndrome,Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05580562Phase 3 · recruiting ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study) · 29 trials list this drug (6 active) | — | — | Glioma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05542407Phase 1 · recruiting ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer · 29 trials list this drug (6 active) | — | — | Carcinosarcoma,Endometrial Endometrioid Adenocarcinoma,Endometrial Mixed Cell Adenocarcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06012929Phase 2 · withdrawn A Study of ONC201 for Refractory Meningioma · 29 trials list this drug (6 active) | — | — | Meningioma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04617002approved for marketing Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas · 29 trials list this drug (6 active) | — | — | Glioma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03295396Phase 2 · terminated ONC201 in Adults With Recurrent H3 K27M-mutant Glioma · 29 trials list this drug (6 active) | — | — | Glioma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03416530Phase 1 · terminated ONC201 in Pediatric H3 K27M Gliomas · 29 trials list this drug (6 active) | — | — | Malignant Glioma,Diffuse Intrinsic Pontine Glioma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02525692Phase 2 · terminated Oral ONC201 in Adult Recurrent Glioblastoma · 29 trials list this drug (6 active) | — | — | Glioblastoma,Thalamic Glioma,Diffuse Midline Glioma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03099499Phase 2 · terminated Single Agent ONC201 in Recurrent or Metastatic Endometrial Cancer · 29 trials list this drug (6 active) | — | — | Malignant Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03485729Phase 2 · terminated ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer · 29 trials list this drug (6 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03034200Phase 2 · completed Phase 2 Study of ONC201 in Neuroendocrine Tumors · 29 trials list this drug (6 active) | — | — | Neuroendocrine Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02863991Phase 1/Phase 2 · terminated Oral ONC201 in Relapsed/Refractory Multiple Myeloma · 29 trials list this drug (6 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04629209Phase 2 · withdrawn A Phase II, Open Label Study of ONC201 in Adults With EGFR-low Glioblastoma · 29 trials list this drug (6 active) | — | — | Glioblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03394027Phase 2 · completed ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma · 29 trials list this drug (6 active) | — | — | Triple-Negative Breast Carcinoma,Malignant Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05392374no longer available Expanded Access Use of ONC201 in a Patient With Diffuse Intrinsic Pontine Gliomas · 29 trials list this drug (6 active) | — | — | Glioma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02420795Phase 1/Phase 2 · terminated Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma · 29 trials list this drug (6 active) | — | — | Central Nervous System Lymphoma,Non-Hodgkin Lymphoma,Gastric Mantle Cell Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03134131no longer available Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline High Grade Gliomas · 29 trials list this drug (6 active) | — | — | Glioma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03733119Phase 2 · terminated ONC201 With a Methionine-Restricted Diet in Patients With Metastatic Triple Negative Breast Cancer · 29 trials list this drug (6 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02609230Phase 1 · completed A Dose-Escalation Study of Onc201 Administered Every One or Three Weeks in Advanced Solid Tumors and Multiple Myeloma · 29 trials list this drug (6 active) | — | — | Solid Neoplasm,Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04854044Phase 1 · withdrawn ONC201 and Radiation Therapy Before Surgery for the Treatment of Recurrent Glioblastoma · 29 trials list this drug (6 active) | — | — | Glioblastoma,Gliosarcoma,Supratentorial Glioblastoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02038699Phase 1/Phase 2 · withdrawn A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer · 29 trials list this drug (6 active) | — | — | Glioblastoma,Lung Non-Small Cell Carcinoma,Malignant Colorectal Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03492138Phase 1/Phase 2 · terminated Ixazomib, ONC201, and Dexamethasone in Relapsed/Refractory Multiple Myeloma · 29 trials list this drug (6 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02250781Phase 1 · completed Oral ONC201 in Treating Patients With Advanced Solid Tumors · 29 trials list this drug (6 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02324621Phase 1 · completed Continuation of Oral ONC201 in Treating Patients With Advanced Solid Tumors · 29 trials list this drug (6 active) | — | — | Adult Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |